• Pressemitteilung BoxID 499835

Genentech and Pfizer Share CDx Success Insights at the 4th Molecular Diagnostics for Cancer Drug Development in Boston

(PresseBox) (London, UK, ) The final agenda has been released for the 4th Molecular Diagnostics for Cancer Drug Development meeting (Boston, June 25th - 28th 2012).

The 3 day agenda features 31 expert speakers including the key project leaders of Zelboraf (Genentech) and Xalkori (Pfizer) on overcoming the scientific and commercial hurdles of targeting a drug to a specific patient subpopulation, and how they gained regulatory approval of their companion diagnostics last year.

They join oncology and diagnostics experts representing: Clovis Oncology, MD Anderson Cancer Center, Johnson & Johnson, National Cancer Institute, Astellas Pharma, Fred Hutchinson Cancer Research Center, The Biomarkers Consortium, Novartis, Daiichi-Sankyo, FDA, ImmunoGen, Bristol-Myers Squibb, Morphotek, Eisai, Bayer, Dana-Farber Cancer Institute, AVEO Pharmaceuticals, Celgene and Merck.

Visit the event website or download the brochure to see the full speaker line up and agenda.

Diese Pressemitteilungen könnten Sie auch interessieren

Patientensicherheit vor Ort: Köln 29.10.2014

, Medizintechnik, Diagramm Halbach GmbH & Co. KG - Produkte für Patientensicherheit

Nach erfolgreichem Auftakt in Bochum und Stuttgart lädt der Veranstalter Diagramm Halbach ein zu einem Business Breakfast zum Thema Patientensicherheit...

BIOSCIENCE Trial Further Confirms Orsiro as Best in Class

, Medizintechnik, BIOTRONIK

The BIOTRONIK Stent is the only Vascular Intervention Product Featured in this Year's ESC Hot Line Sessions. Late-breaking results of the...

BIOSCIENCE Studie bestätigt ersten Medikament-freisetzenden Hybrid-Stent Orsiro als "best in class"

, Medizintechnik, BIOTRONIK

Der Stent von BIOTRONIK ist das einzige Produkt aus dem Bereich der Vaskulären Intervention, dessen hervorragende Ergebnisse im Rahmen der diesjährigen...

Disclaimer